A Chinese cohort study of patients with pancreatic ductal adenocarcinoma also revealed that GGT can be used as a potential prognostic indicator for metastatic pancreatic cancer, adjusting for age, chemotherapy status, fasting glucose, and albumin, but its prognostic value may also be affected by metabolic factors such as alcohol, obesity, and NAFLD [113]. This evidence concerns the gene GGTLC3 and metabolic dysfunction-associated steatotic liver disease.